KEYNEUROTEK AG ANNOUNCES COLLABORATION AGREEMENT WITH SCHWARZ PHARMA

KeyNeurotek AG today announced the start of a research collaboration with SCHWARZ PHARMA Group, Monheim, Germany. SCHWARZ PHARMA will use KeyNeurotek's TELOMICSTM platform to characterize drug candidates for its urology program. Dr. Frank Striggow, Chief Executive Officer of KeyNeurotek, said: "We are proud that Schwarz Pharma has chosen KeyNeurotek as its partner. This underlines the compliance of our TELOMICSTM technology."

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20612520&full=1)